Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

There's a Lot More to Being a Physician: Insights From an Intensive Clinical Shadowing Experience in Internal Medicine
Block, Lauren , Gao, Catherine C. , Wu, Albert W. , Wu, Albert W , Wang, Kevin Y. , Feldman, Leonard Samuel

Mayo Clinic

Teaching and Learning in Medicine | January 29, 2018 | Volume: 30 | Issue: 3 | Pages: 266-273

10.1080/10401334.2017.1415148 | PMID 29377731 Get It

Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery
Piccini, Jonathan P. , Wang, Tongrong, Malaisrie, S. Chris, Holmes, David R. , Suri, Rakesh M. , Mack, Michael J. , Badhwar, Vinay , Gaca, Jeffrey G., Chow, Shein‐Chung, Brennan, James M. , Malaisrie, S. Chris , Friedman, Daniel J , Zheng, Jiayin , Jacobs, Jeffrey P. , Peterson, Eric D.

Mayo Clinic

JAMA | January 23, 2018 | Volume: 319 | Issue: 4 | Pages: 365

10.1001/jama.2017.20125 | PMID 29362794 Get It

Integrated transcriptomic and regulatory network analyses identify microRNA-200c as a novel repressor of human pluripotent stem cell-derived cardiomyocyte differentiation and maturation
Hao, Baixia , Guan, Daogang , Li, Mulin Jun , Lu, Jun, Yang, Yong , Wu, Binbin , Wu, Stanley Chun-ming, Webb, Sarah , Liang, Yan , Yao, Xiaoqiang , Wang, Junwen , Yan, Bin , Wang, Junwen , Poon, Ellen Ngar-Yun , Miller, Andrew L. , Boheler, Kenneth R.

Mayo Clinic

Cardiovascular Research | January 22, 2018 | Volume: 114 | Issue: 6 | Pages: 894-906

10.1093/cvr/cvy019 | PMID 29373717 Get It

Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
Vinereanu, Dragoş , Wang, Alice , Mulder, Hillary , Janský, Petr, Avezum, Álvaro , Hanna, Michael , Held, Claes , Wallentin, Lars , Granger, Christopher B. , Alexander, John H. , Hanna, Michael G. , Granger, Christopher B , Lópes, Renato D. , Lewis, Basil S. , Gersh, Bernard J. , Held, Claes , Mulder, Hillary

Mayo Clinic

Heart | January 19, 2018 | Volume: 104 | Issue: 15 | Pages: 1292-1299

10.1136/heartjnl-2017-312272 | PMID 29352007 Get It

Objective To assess stroke/systemic embolism, major bleeding and other outcomes, and treatment effect of apixaban versus warfarin, in patients with atrial fibrillation (AF) and different types of valvular heart disease (VHD), using data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Methods There were 14 793 patients with known VHD status, categorised as having moderate or severe mitral regurgitation (MR) (n=3382), aortic regurgitation (AR) (n=842) or aortic stenosis (AS) (n=324); patients with moderate or severe mitral stenosis were excluded from the trial. Baseline characteristics, efficacy and safety outcomes were compared between each type and no significant VHD. Treatment effect was assessed using an adjusted model. Results Patients with MR or AR had similar rates of stroke/systemic embolism and bleeding compared with patients without MR or AR, respectively. Patients with AS had significantly higher event rates (presented as rate per 100 patient-years of follow-up) of stroke/systemic embolism (3.47 vs 1.36; adjusted HR (adjHR) 2.21, 95% CI 1.35 to 3.63), death (8.30 vs 3.53; adjHR 1.92, 95% CI 1.41 to 2.61), major bleeding (5.31 vs 2.53; adjHR 1.80, 95% CI 1.19 to 2.75) and intracranial bleeding (1.29 vs 0.51; adjHR 2.54, 95% CI 1.08 to 5.96) than patients without AS. The superiority of apixaban over warfarin on stroke/systemic embolism was similar in patients with versus without MR (HR 0.69, 95% CI 0.46 to 1.04 vs HR 0.79, 95% CI 0.63 to 1.00; interaction P value 0.52), with versus without AR (HR 0.57, 95% CI 0.27 to 1.20 vs HR 0.78, 95% CI 0.63 to 0.96; interaction P value 0.52), and with versus without AS (HR 0.44, 95% CI 0.17 to 1.13 vs HR 0.79, 95% CI 0.64 to 0.97; interaction P value 0.19). For each of the primary and secondary efficacy and safety outcomes, there was no evidence of a different effect of apixaban over warfarin in patients with any VHD subcategory. Conclusions In anticoagulated patients with AF, AS is associated with a higher risk of stroke/systemic embolism, bleeding and death. The efficacy and safety benefits of apixaban compared with warfarin were consistent, regardless of presence of MR, AR or AS. Clinical trial registration ARISTOTLE clinical trial number NCT00412984.
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, Joshua D. , Li, Lu , Wang, Yuxuan , Thoburn, Christopher J. , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A. , Wong, Fay , Mattox, Austin K. , Hruban, Ralph H. , Wolfgang, Christopher L. , Molin, Marco Dal , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Browne, J. Dale, Tie, Jeanne , Wong, Hui‐Li , Mansfield, Aaron S. , Jen, Jin , Falconi, Massimo , Allen, Peter J. , Zhou, Shibin , Díaz, Luis A. , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Thoburn, Christopher , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A , Wong, Fay , Mattox, Austin , Wolfgang, Christopher L , Roden, Richard , Klein, Alison P , Ptak, Janine , Dobbyn, Lisa , Schaefer, Joy , Silliman, Natalie , Schoen, Robert E , Brand, Randall E , Tie, Jeanne , Wong, Hui-Li , Mansfield, Aaron S , Jen, Jin , Zhou, Shibin , Diaz, Luis A , Tomasetti, Cristian , Kinzler, Kenneth W , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Wang, Yuxuan , Afsari, Bahman , Goggins, Michael , Wang, Tian‐Li , Klein, Alison P. , Popoli, Maria , Vogelstein, Joshua T , Schoen, Robert E. , Brand, Randall E. , Gibbs, Peter , Hanash, Samir , Bettegowda, Chetan , Massimo, Falconi

Mayo Clinic

Science | January 18, 2018 | Volume: 359 | Issue: 6378 | Pages: 926-930

10.1126/science.aar3247 | PMID 29348365 Get It

SEEK and you may find cancer earlier Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid genetic evolution limits its response to drugs, have fueled interest in methodologies for earlier detection of the disease. Cohen et al. developed a noninvasive blood test, called CancerSEEK that can detect eight common human cancer types (see the Perspective by Kalinich and Haber). The test assesses eight circulating protein biomarkers and tumor-specific mutations in circulating DNA. In a study of 1000 patients previously diagnosed with cancer and 850 healthy control individuals, CancerSEEK detected cancer with a sensitivity of 69 to 98% (depending on cancer type) and 99% specificity. Science , this issue p. 926 ; see also p. 866
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Jain, Apurva , Kelley, Robin Kate , Wáng, Ying , Baggerly, Keith, Al‐Shamsi, Humaid O. , Ahn, Daniel H. , DeLeon, Thomas, Bocobo, Andrea Grace, Bekaii‐Saab, Tanios , Shroff, Rachna T. , Javle, Milind , Abdel-Wahab, Reham, Meric-Bernstam, Funda, Baggerly, Keith A, Kaseb, Ahmed Omar, Al-Shamsi, Humaid O, Bekaii-Saab, Tanios S , Borad, Mitesh J. , Abdel‐Wahab, Reham , Meric‐Bernstam, Funda , Kaseb, Ahmed O , Al-Shamsi, Humaid O

Mayo Clinic

JCO Precision Oncology | January 17, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-12

10.1200/po.17.00080 | PMID 35135097 Get It

Purpose FGFR genetic aberrations (GAs) occur in an estimated 10% to 16% of intrahepatic cholangiocarcinomas (CCAs). The natural history of CCA with FGFR GAs, the prognostic role of coexisting GAs, and the outcome with FGFR-targeted inhibitors are unknown. Patients and Methods Patients with CCA with FGFR GAs were identified using next-generation sequencing or fluorescence in situ hybridization from four tertiary cancer centers and compared with FGFR wild-type counterparts. Data reviewed included demographic, treatment, overall survival (OS), and GA data. Fisher’s exact test, Kaplan-Meier plots, and log-rank tests were used for statistical analysis. Results Three hundred seventy-seven patients with CCA were identified, and 95 had FGFR GAs. FGFR2 GA was most common (n = 74, with 63 fusions) and seen in intrahepatic CCA. In patients with CCA, FGFR GAs occurred more frequently in younger patients (≤ 40 years; 20%) compared with older patients (> 40 years; 6.7%; P < .001), presented at an earlier stage (TNM stage I/II v III/IV: 35.8% v 22%, respectively; P = .001), and were associated with a longer OS compared with patients without FGFR GAs (37 v 20 months, respectively; P < .001). This difference remained significant after excluding 36 patients treated with FGFR inhibitors. There was no OS difference ( P = .60) between CCA with FGFR2 fusions (n = 63) versus other FGFR GAs (n = 29). Patients with FGFR GAs had a better OS with FGFR-targeted therapy compared with standard treatment ( P = .01). BAP1 mutation was the most common coexisting mutation without prognostic impact, whereas TP53 ( P = .04) and CDKN2A/B ( P = .04) were correlated with a shorter OS. Conclusion CCA with FGFR GAs represents a unique subtype occurring in younger patients with an indolent disease course. FGFR-targeted therapy may have a positive impact on OS in this subgroup.
Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus
Moinova, Helen , LaFramboise, Thomas , Lutterbaugh, James, Chandar, Apoorva K., Dumot, John A. , Faulx, Ashley L., Brock, Wendy , Cabrera, Omar De la Cruz , Guda, Kishore , Barnholtz‐Sloan, Jill S. , Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanti N., Willis, Joseph , Chak, Amitabh , Markowitz, Sanford D. , Moinova, Helen R , De la Cruz Cabrera, Omar , Willis, Joseph E , Chak, Amitabh , Markowitz, Sanford D , Barnholtz-Sloan, Jill S , Canto, Marcia Irene

Mayo Clinic

Science Translational Medicine | January 17, 2018 | Volume: 10 | Issue: 424 | Pages: No page available

10.1126/scitranslmed.aao5848 | PMID 29343623 Get It

Combining DNA methylation markers with a swallowable device for sampling the distal esophagus effectively detects Barrett’s neoplasias.
Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A 1c , LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study
Ikramuddin, Sayeed , Körner, Judith , Thomas, Avis J., Connett, John E. , Bantle, John P., Leslie, Daniel B. , Wang, Qi , Inabnet, William B. , Jeffery, Robert W., Chong, Keong , Chuang, Lee‐Ming , Jensen, Michael D. , Ahmed, Leaque , Belani, Kumar G. , Lee, Wei‐Jei , Vella, Adrian , Billington, Charles J.

Mayo Clinic

JAMA | January 16, 2018 | Volume: 319 | Issue: 3 | Pages: 266

10.1001/jama.2017.20813 | PMID 29340678 Get It

Three‐Dimensional Shear Wave Elastography for Differentiating Benign From Malignant Thyroid Nodules
Zhao, Chong‐Ke , Chen, Shigao , He, Ya‐Ping, Wang, Qiao , Wang, Dan , Yue, Wenwen , Zhang, Kun , Wei, Qing , Xu, Hui‐Xiong, Chen, Shi-Gao, Alizad, Azra , He, Ya‐Ping, Qu, Shen , Xu, Hui‐Xiong

Mayo Clinic

Journal of Ultrasound in Medicine | January 10, 2018 | Volume: 37 | Issue: 7 | Pages: 1777-1788

10.1002/jum.14531 | PMID 29315789 Get It

ObjectivesTo prospectively evaluate the diagnostic performance of 3‐dimensional (3D) shear wave elastography (SWE) for assessing thyroid nodules.MethodsA total of 176 surgically or cytologically confirmed thyroid nodules (63 malignant and 113 benign) in 176 patients who had undergone conventional ultrasound (US), 2‐dimensional (2D) SWE, and 3D SWE examinations were included in this study. Quantitative elasticity values (mean elasticity, maximum elasticity, and standard deviation of elasticity of a large region of interest and mean elasticity of a 2‐mm region of interest) were measured on 2D and 3D SWE. Diagnostic performances of conventional US, 2D SWE, and 3D SWE were assessed. The role of 2D and 3D SWE in reducing unnecessary fine‐needle aspiration (FNA) for nodules with low suspicion was also evaluated.ResultsThe diagnostic performances in terms of the area under the receiver operating characteristic curve were 0.612 for conventional US, 0.836 for 2D SWE (P < .001 in comparison with conventional US), and 0.839 for 3D SWE (P < .001 in comparison with conventional US). The mean elasticity achieved the highest diagnostic performance in 2D SWE, whereas the standard deviation of elasticity achieved the highest performance in 3D SWE, although no significant difference was found between them (P > .05). Three‐dimensional SWE increased the specificity in comparison with 2D SWE (88.5% versus 82.3%; P = .039). For the 37 nodules with low suspicion on conventional US imaging, 2D SWE was able to avoid unnecessary FNA in 77.1% (27 of 35) of benign nodules, and 3D SWE further increased the number to 88.6% (31 of 35).ConclusionsThree‐dimensional SWE is a useful tool for predicting thyroid nodule malignancy and reducing unnecessary FNA procedures in thyroid nodules with low suspicion of malignancy.
Impact of sleep deprivation on the outcomes of percutaneous coronary intervention
Iverson, Ann , Stanberry, Larissa , Garberich, Ross , Antos, Amber, Sandoval, Yader , Burke, M. Nicholas , Chavez, Ivan , Gössl, Mario , Henry, Timothy D. , Lips, Daniel, Poulose, Anil, Sorajja, Paul , Wang, Yale , Sorajja, Paul , Brilakis, Emmanouil S , Nicholas Burke, M , Mooney, Michael R , Traverse, Jay H. , Bradley, Steven M. , Brilakis, Emmanouil S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 3, 2018 | Volume: 92 | Issue: 6 | Pages: 1118-1125

10.1002/ccd.27471 | PMID 29314592 Get It

AbstractObjectivesThis study sought to compare the clinical outcomes of percutaneous coronary interventions (PCIs) performed by sleep deprived and non‐sleep deprived operators.BackgroundInterventional cardiologists are at risk for sleep deprivation as they often have to perform emergent procedures at night, but the effects of sleep deprivation on clinical outcomes have received limited study.MethodsWe examined the frequency, clinical characteristics, and outcomes of daytime PCIs performed by sleep deprived and non‐sleep deprived operators at a tertiary medical center. Operators were considered sleep deprived when performing a daytime (7 am–11:59 pm) procedure preceded by a nighttime (12 am–6:59 am) procedure on the same date.ResultsOf the 12,680 daytime PCIs performed from 6/29/09 to 12/30/2016, 367 (2.9%) were performed by sleep deprived operators. Patients undergoing PCI performed by a sleep deprived operator were more likely to be younger, white, and to present with ST‐elevation acute myocardial infarction (STEMI). The incidence of in‐hospital death (1.1% vs. 1.3%, P = 1.0) and bleeding within 72 hr (3.9% vs. 2.9%, P = 0.29) were similar for procedures performed by sleep‐deprived and non‐sleep deprived operators. When the sleep deprived group was further stratified based on degree of sleep deprivation or length of sleep interruption, differences in mortality and total bleeding remained non‐significant.ConclusionsIn this large single center study, operator sleep deprivation did not appear to adversely impact PCI outcomes.